Study wrapper · #1019
Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response?
La Vignera S, Condorelli RA Journal of the Endocrine Society. 2026.
DOI: 10.1210/jendso/bvag149PubMed: 42487666
Editor's note
A narrative review synthesizing pharmacogenomic data on how GLP1R and GIPR polymorphisms relate to variability in response to semaglutide and tirzepatide. The associations described are drawn largely from earlier genetic studies and remain hypothesis-generating; the authors note that population-specific prospective data are still limited. Useful as background on why individual responses differ, rather than as clinically actionable guidance.
Plain-language abstract
This review examines how genetic differences in the GLP-1 and GIP receptors may explain why people respond differently to semaglutide and tirzepatide. Certain receptor variants are associated with differences in weight loss, blood-sugar changes, and side effects such as nausea.
Related coverage
Weak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health caren=——2026
Mixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicinen=——2026
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026